Signal from the log
Ollin Biosciences
330 M$ · Series B · United States · Biotech
Biotech américaine qui développe OLN324, un anticorps bispécifique visant VEGF et Ang2 contre l'œdème maculaire diabétique et la dégénérescence maculaire liée à l'âge. Dans un essai de phase 1b en comparaison directe, il a fait mieux que le Vabysmo de Genentech sur les gains visuels. Les phases 3 démarrent au second semestre 2026.
Verified
Announced on , logged by the watch of 12 August 2026.
- Operation
- Funding round
- Announced amount
- 330 M$
- Stage
- Series B
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by TCGX , ARCH Venture Partners , with Blackstone Multi-Asset Investing , Commodore Capital , RA Capital Management
Provenance
Source longevity
Logged on 12 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.